Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.
2.

Effect of first-line antituberculosis therapy on nevirapine pharmacokinetics in children younger than 3 years old.

Enimil A, Antwi S, Yang H, Dompreh A, Alghamdi WA, Gillani FS, Orstin A, Bosomtwe D, Opoku T, Norman J, Wiesner L, Langaee T, Peloquin CA, Court MH, Greenblatt DJ, Kwara A.

Antimicrob Agents Chemother. 2019 Jul 22. pii: AAC.00839-19. doi: 10.1128/AAC.00839-19. [Epub ahead of print]

PMID:
31332062
3.

Longitudinal HIV Transmission Risk Profiles Among Men Who Have Sex With Men Living With HIV in the SUN Study.

van den Berg JJ, Zaller ND, Gillani FS, Dunsiger SI, Marshall BDL, Kahler CW, Operario D.

Am J Mens Health. 2019 Jan-Feb;13(1):1557988318818283. doi: 10.1177/1557988318818283. Epub 2018 Dec 12.

PMID:
30541366
4.

Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.

Kwara A, Yang H, Antwi S, Enimil A, Gillani FS, Dompreh A, Ortsin A, Opoku T, Bosomtwe D, Sarfo A, Wiesner L, Norman J, Alghamdi WA, Langaee T, Peloquin CA, Court MH, Greenblatt DJ.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01657-18. doi: 10.1128/AAC.01657-18. Print 2019 Jan.

5.

Causes of death and factors associated with early mortality of HIV-infected adults admitted to Korle-Bu Teaching Hospital.

Saavedra A, Campinha-Bacote N, Hajjar M, Kenu E, Gillani FS, Obo-Akwa A, Lartey M, Kwara A.

Pan Afr Med J. 2017 May 18;27:48. doi: 10.11604/pamj.2017.27.48.8917. eCollection 2017.

6.

Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Yang H, Enimil A, Gillani FS, Antwi S, Dompreh A, Ortsin A, Adu Awhireng E, Owusu M, Wiesner L, Peloquin CA, Kwara A.

Pediatr Infect Dis J. 2018 Jan;37(1):43-51. doi: 10.1097/INF.0000000000001687.

7.

Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.

Antwi S, Yang H, Enimil A, Sarfo AM, Gillani FS, Ansong D, Dompreh A, Orstin A, Opoku T, Bosomtwe D, Wiesner L, Norman J, Peloquin CA, Kwara A.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01701-16. doi: 10.1128/AAC.01701-16. Print 2017 Feb.

8.

Obesity prevalence and related risk of comorbidities among HIV+ patients attending a New England ambulatory centre.

Becofsky KM, Wing EJ, Wing RR, Richards KE, Gillani FS.

Obes Sci Pract. 2016 Jun;2(2):123-127. doi: 10.1002/osp4.38. Epub 2016 May 31.

9.

Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.

Archampong TN, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, Gillani FS, Yang H, Boamah I, Flanigan T, Kwara A.

BMC Infect Dis. 2016 Jan 13;16:14. doi: 10.1186/s12879-016-1342-4.

10.

Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.

Kwara A, Enimil A, Gillani FS, Yang H, Sarfo AM, Dompreh A, Ortsin A, Osei-Tutu L, Kwarteng Owusu S, Wiesner L, Norman J, Kurpewski J, Peloquin CA, Ansong D, Antwi S.

J Pediatric Infect Dis Soc. 2016 Dec;5(4):356-365. Epub 2015 May 26.

11.

Multiple gaps in care common among newly diagnosed HIV patients.

Rana AI, Liu T, Gillani FS, Reece R, Kojic EM, Zlotnick C, Wilson IB.

AIDS Care. 2015;27(6):679-87. doi: 10.1080/09540121.2015.1005002. Epub 2015 Jan 29.

12.

Monitored viral load: a measure of HIV treatment outcomes in an outpatient setting in Rhode Island.

Touzard Romo F, Gillani FS, Ackerman P, Rana A, Kojic EM, Beckwith CG.

R I Med J (2013). 2014 Jan 5;98(1):26-30.

13.

Decade of HIV in Rhode Island: demographic and clinical characteristics of patients diagnosed in 2001 and 2010.

Leeper S, Fillion K, Gillani FS, Rana A, Tashima K, Ross H.

R I Med J (2013). 2013 Feb 1;96(2):35-40.

14.

Evaluation of longitudinal clinical outcomes and adherence to care among HIV-infected refugees.

Winston SE, Montague BT, Lopez MJ, Delong A, Lemarchand C, Bedoya A, Gillani FS, Beckwith CG.

J Int Assoc Provid AIDS Care. 2013 May-Jun;12(3):202-7. doi: 10.1177/1545109712459680. Epub 2012 Sep 28.

15.

Cardiovascular health of HIV-infected African-American women at the Miriam Hospital Immunology Center in Providence, RI.

Zachary D, Gillani FS, Najfi N, Casarella R, Tashima K.

Med Health R I. 2012 Jun;95(6):179-82. No abstract available.

16.

Impact of immigration on the molecular epidemiology of tuberculosis in Rhode Island.

Vanhomwegen J, Kwara A, Martin M, Gillani FS, Fontanet A, Mutungi P, Crellin J, Obaro S, Gosciminski M, Carter EJ, Rastogi N.

J Clin Microbiol. 2011 Mar;49(3):834-44. doi: 10.1128/JCM.01952-10. Epub 2010 Dec 15.

17.

Short communication: Transmitted drug resistance and molecular epidemiology in antiretroviral naive HIV type 1-infected patients in Rhode Island.

Chan PA, Tashima K, Cartwright CP, Gillani FS, Mintz O, Zeller K, Kantor R.

AIDS Res Hum Retroviruses. 2011 Mar;27(3):275-81. doi: 10.1089/aid.2010.0198. Epub 2010 Oct 18.

18.

Follow-up care among HIV-infected pregnant women in Mississippi.

Rana AI, Gillani FS, Flanigan TP, Nash BT, Beckwith CG.

J Womens Health (Larchmt). 2010 Oct;19(10):1863-7. doi: 10.1089/jwh.2009.1880.

19.

Changes in demographics and risk factors among persons living with HIV in an academic medical center from 2003-2007.

Gillani FS, Zaller ND, Zeller K, Rich JD, Cu-Uvin S, Flanigan TP, Carpenter CC.

Med Health R I. 2009 Jul;92(7):237-40. No abstract available.

20.

Supplemental Content

Loading ...
Support Center